Age-specific risk of musculoskeletal and neurological disorders following fluoroquinolone exposure among children aged <18 years.
文献摘要
Background Quantifying the risk of fluoroquinolone-associated musculoskeletal and neurological adverse event among children stratified supports clinicians to select the most appropriate antimicrobial regimen for children with bacterial infection. The objective of this study was to assess the risk of musculoskeletal and neurological disorders following fluoroquinolone exposure, compared with another antimicrobial class using the large-scale database. Methods This retrospective study used the TriNetX platform, a multicenter health record database, to compare risk of musculoskeletal and neurological disorders following fluoroquinolone versus macrolide exposure in children aged Results In the United States, 423,880, 380,504 and 194,220 children aged Conclusion This study showed the increased risk of peripheral neuropathy and sleep disorder following fluoroquinolones use among children compared with macrolide use. This study provided the data for clinicians to estimate risks of musculoskeletal or neurological adverse events.